PRUCALOPRIDE 2mg. IP

A prokinetic agent that treats chronically constipated patients. Possesses gastrointestinal and colonic prokinetic properties. (E P Bouras, 2001) A potent stimulator of gut motility. (Quigley, 2012) A promising alternative therapy in patients dissatisfied with conventional laxatives. (Quigley, 2012) A valuable medicine in various motility disorders such as gastroparesis. (Hong, 2021) Provides an additional treatment option for patients with chronic idiopathic constipation. (Garnock-Jones, 2016) Significantly and consistently ameliorates the movement of the bowel. (J Tack, 2009) Proved to be a potential treatment for small and large bowel disorders. (M Ke, 2012) Has a rapid onset of enterokinetic activity and causes loosening of stool in patients with chronic constipation. (Coremans, 2008), (Banny S Wong, 2010) Improves the gastric emptying rate and symptoms in patients with gastroparesis. (Carbone, et al., 2019) A very well-tolerated drug with fewer cardiac events than Cisapride and Tegaserod. (Banny S Wong, 2010) Increases stool frequency, reduces constipation-related symptoms and improves the quality of life. (Kay Diederen, 2015)